NO976122L - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents

AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes

Info

Publication number
NO976122L
NO976122L NO976122A NO976122A NO976122L NO 976122 L NO976122 L NO 976122L NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 L NO976122 L NO 976122L
Authority
NO
Norway
Prior art keywords
assay method
ligand antibodies
phase ligand
phase
antibodies
Prior art date
Application number
NO976122A
Other languages
English (en)
Other versions
NO976122D0 (no
NO324120B1 (no
Inventor
Kamon Shirakawa
Tomokazu Matsusue
Shigekazu Nagata
Man Sung Co
Maximiliano Vasquez
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/649,100 external-priority patent/US6114507A/en
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Publication of NO976122D0 publication Critical patent/NO976122D0/no
Publication of NO976122L publication Critical patent/NO976122L/no
Publication of NO324120B1 publication Critical patent/NO324120B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
NO19976122A 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. NO324120B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18848095 1995-06-30
US08/649,100 US6114507A (en) 1995-06-30 1996-05-17 Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
PCT/JP1996/001820 WO1997002290A1 (fr) 1995-06-30 1996-07-01 ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR

Publications (3)

Publication Number Publication Date
NO976122D0 NO976122D0 (no) 1997-12-29
NO976122L true NO976122L (no) 1998-02-27
NO324120B1 NO324120B1 (no) 2007-08-27

Family

ID=26504954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976122A NO324120B1 (no) 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene.

Country Status (8)

Country Link
EP (1) EP0842948B1 (no)
JP (1) JP3925663B2 (no)
CN (1) CN1196733A (no)
AU (1) AU724856B2 (no)
CA (1) CA2225852C (no)
NO (1) NO324120B1 (no)
NZ (1) NZ311174A (no)
WO (1) WO1997002290A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777540B1 (en) 1996-09-02 2004-08-17 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
EP1029550A4 (en) 1997-11-10 2001-09-26 Mochida Pharm Co Ltd PREVENTIVE AND THERAPEUTIC DRUGS FOR DIFFUSED PULMONARY CONDITIONS
ATE357931T1 (de) 1998-02-06 2007-04-15 Mochida Pharm Co Ltd Mittel zur prävention/behandlung entzündlicher darmerkrankungen
WO1999058150A1 (fr) * 1998-05-14 1999-11-18 Mochida Pharmaceutical Co., Ltd. Agents preventifs/remedes contre la cirrhose du foie
DE69932434D1 (de) * 1998-05-29 2006-08-31 Mochida Pharm Co Ltd Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
JP4734739B2 (ja) * 2000-09-29 2011-07-27 東レ株式会社 哺乳動物のガン抑制方法
DE60315815T2 (de) * 2002-03-21 2008-05-21 Eli Lilly And Co., Indianapolis ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
CA2510180C (en) * 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
KR20120035234A (ko) * 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 il?9 항체 및 그의 용도
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
AU2007341631B9 (en) 2006-12-28 2012-10-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
PT2231708E (pt) * 2007-12-12 2015-07-30 Pincell Srl Remédios para pênfigo contendo anticorpos anti-ligando de faz
CN101965403B (zh) 2008-01-29 2013-07-03 株式会社抗体研究所 A型肉毒杆菌毒素中和组合物及人抗a型肉毒杆菌毒素抗体
PT2376536E (pt) 2008-12-12 2015-05-11 Pincell Srl Remédios para pênfigo contendo anticorpos anti-ligando de faz
WO2011010156A1 (en) * 2009-07-21 2011-01-27 Queen Mary & Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
RU2744836C2 (ru) * 2014-05-08 2021-03-16 Новодиакс, Инк. Прямой иммуногистохимический анализ
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
JP6884785B2 (ja) * 2015-09-23 2021-06-09 アポジェニックス アーゲー 抗cd95l抗体
LT3592392T (lt) * 2017-03-10 2024-01-25 University Of Louisville Research Foundation, Inc. Fasl modifikuotos biomedžiagos su imunomoduliacine funkcija
CN116888257A (zh) * 2022-01-21 2023-10-13 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用
WO2023208990A1 (en) 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2174132A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Fas抗原に結合する新規蛋白質およびそれをコードするDNA
JPH09508009A (ja) * 1994-01-07 1997-08-19 イミュネックス・コーポレーション Fas抗原を結合するリガンド
JP3451092B2 (ja) * 1995-03-20 2003-09-29 康 奥村 Fasリガンドに特異的に反応するモノクローナル抗体及びその製造方法

Also Published As

Publication number Publication date
JP3925663B2 (ja) 2007-06-06
EP0842948A4 (en) 2004-12-15
WO1997002290A1 (fr) 1997-01-23
NO976122D0 (no) 1997-12-29
NO324120B1 (no) 2007-08-27
AU6243596A (en) 1997-02-05
CA2225852C (en) 2009-04-14
AU724856B2 (en) 2000-10-05
EP0842948B1 (en) 2009-04-22
EP0842948A1 (en) 1998-05-20
CA2225852A1 (en) 1997-01-23
NZ311174A (en) 1999-04-29
CN1196733A (zh) 1998-10-21

Similar Documents

Publication Publication Date Title
NO976122L (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
NO996551D0 (no) Forbedrete anti-IgE-antistoffer og fremgangsmåte for forbedring av polypeptider
ID19197A (id) Pesawat pengolah informasi dan metode pengolah informasi
DE69632366D1 (de) Probenfördereinrichtung
DE69732511D1 (de) Verarbeitungsverfahren für Signale von Objekten mit sich bewegenden Teilen und Echographie-Vorrichtung dafür
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
DK0825946T3 (da) Fremgangsmåde til lastning og behandling af hydrocarboner
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
FI101829B1 (fi) Biospesifinen määritysmenetelmä
DE69638207D1 (de) Prozessor und Verarbeitungsverfahren für Dokumente
DE69427123T2 (de) Screeningverfahren für katalytische nicht-enzym-polypeptide und-proteine
EP0645630A3 (en) Method for determining the presence of a pivka and reagent therefor.
EP0870826A4 (en) NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE
DE69608277T2 (de) Probenanalysegerät
DE69409379D1 (de) Ultraschallabtastgerät und -verfahren
EP0699909A3 (en) Method for the determination of fibrinogen and reagent for its determination
KR970703146A (ko) 류마티스성 관절염의 치료방법 및 시약(method and reagents for the treatment of rheumatoid arthritis)
DE69426354D1 (de) Reagenz zur bestimmung von glucose
ZA944024B (en) Immunoassay reagents and methods for detecting brequinar and analoges
DK0780388T3 (da) 5HT1Dalfa og 5HT2A ligander
DE69618904T2 (de) Probenanalyse
FI931151A (fi) Biospesifinen määritysmenetelmä
FI971754A0 (fi) Vasta-ainereagenssi kalvoja irtauttavan aortan pullistuman osittamiseksi ja sen käyttö
KR970001553A (ko) 인간 파르보비루스의 검출 방법 및 이를 위한 시약
DE69322179D1 (de) Verfahren und Reagenzien für Immunoassay